NCT01858168View on ClinicalTrials.gov

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

November 1, 2024

Study Completion Date

December 31, 2025

Conditions
Ewing SarcomaRhabdomyosarcoma
Interventions
DRUG

Olaparib

Tablets to be taken on an empty stomach twice a day.

DRUG

Temozolomide

Tablets to be taken on an empty stomach before bedtime.

DRUG

Irinotecan

Administered via IV

Trial Locations (5)

38105

St. Jude's Children's Research Hospital, Memphis

02114

Massachusetts General Hospital, Boston

02115

Boston Children's Hospital, Boston

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER